[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertrophic-obstructive-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertrophic-obstructive-cardiomyopathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100446975","hypertrophic-cardiomyopathy-registry-biobank-and-imaging-data-repository-100446975",false,"NCT05100420","Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository","Hearts in Rhythm Organization Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository (HiRO-HCM)","HiRO-HCM","Inclusion Criteria:\n\nPatients with (1) AND\u002FOR (2)\n\n1. Clinical diagnosis of HCM, defined as\n\n   1. maximal LVWT ≥15mm, or\n   2. maximal LVWT ≥13mm, in presence of a diagnosis of first degree relative with HCM, or\n   3. septal wall thickness with z-score \\>2 in a child\n\n   AND\u002FOR\n2. Carrier of a pathogenic or likely pathogenic genetic variant in a sarcomeric gene (ACTC1, FHOD3, MYBPC3, MYH7, MYL2, MYL3, TNNI3, TNNT2, TPM1). Variant classification should be performed by a certified diagnostic laboratory according to the American College of Medical Genetics and Genomics (ACMG) guidelines.\n\nExclusion Criteria:\n\n1. Clinical or molecular diagnosis of Noonan syndrome or other Rasopathies\n2. Clinical or molecular diagnosis of metabolic disease associated with cardiomyopathy, such as Pompe (GAA), Fabry (GLA), Danon (LAMP2), AMP-kinase (PRKAG2), and carnitine disorders\n3. Clinical diagnosis of a neuromuscular disease associated with cardiomyopathy, such as Friedrich's ataxia\n4. Clinical diagnosis of cardiac amyloidosis with or without the presence of genetic variants in TTR\n5. Clinical or molecular diagnosis of mitochondrial cardiomyopathy\n6. Diagnosis of HCM \\>65 years old AND absence of pathogenic or likely pathogenic variant in a sarcomeric gene (as defined in inclusion criterion 1B above)\n7. History of myocardial infarction\n8. History of moderate or severe aortic stenosis\n9. History of congenital heart defects requiring percutaneous or surgical correction\n10. History of severe hypertension defined as a systolic blood pressure \\>180 mmHg and\u002For diastolic blood pressure \\>110 mmHg AND absence of pathogenic or likely pathogenic variant in a sarcomeric gene (as defined in inclusion criterion 1B above)\n11. Refusal to provide informed consent or to provide a biospecimen for DNA analysis\n12. No possibility to upload transthoracic echocardiogram or cardiac magnetic resonance imaging for core lab interpretation","ALL",{"count":19,"type":20},2000,"ESTIMATED","5 Years","OBSERVATIONAL","The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers\u002Fclinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD). The HiRO Hypertrophic Cardiomyopathy registry, biobank and imaging data repository (HiRO-HCM) is a multicenter study that will prospectively enroll patients with HCM as well as those carrying sarcomeric gene variants predisposing to HCM.\n\nThe objectives of HiRO-HCM are:\n\n1. to better understand the natural history of the disease and identify clinical markers and biomarkers for adverse outcomes;\n2. to derive and validate risk prediction models for disease expression, complications and response to therapy;\n3. to better define the genetic architecture of sarcomeric and non-sarcomeric HCM.",[25,26,27,28],"Hypertrophic Cardiomyopathy","Hypertrophic Obstructive Cardiomyopathy","Familial Hypertrophic Cardiomyopathy","Cardiomyopathies",[30,31,32,33,34,35,36],"Genetics","Echocardiography","Cardiac magnetic resonance imaging","Biomarker","Sudden cardiac death","Genome-wide association study","Risk prediction model","RECRUITING","2026-10-06",{"date":40,"type":41},"2026-10-09","ACTUAL",{"date":43,"type":41},"2021-02-23",{"date":45,"type":20},"2035-12-31",{"name":47,"class":48},"Montreal Heart Institute","OTHER",17,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100464822","transapical-beating-heart-septal-myectomy-in-patient-with-hypertrophic-obstructive-cardiomyopathy-100464822","NCT05332691","Transapical Beating-heart Septal Myectomy in Patient With Hypertrophic Obstructive Cardiomyopathy","Minimally Invasive Transapical Septal Myectomy in the Beating Hearts for the Treatment of Hypertrophic Obstructive Cardiomyopathy: Safety and Efficacy Results of a Phase I First-in-man Clinical Trial","Inclusion Criteria:\n\n1. Patients whose resting or provoked left ventricular outflow tract gradient \\> 50 mmHg, and maximal ventricular septal wall thickness ≥ 15 mm.\n2. Patients with heart function of New York Heart Association ≥ class II.\n3. Patients with drug-refractory symptoms or intolerable to pharmaceutical therapies.\n4. Patients who was informed the nature of the clinical trial, consented to participate in all of the activities of the clinical trial, and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients who were pregnant.\n2. Patients who had concomitant diseases such as intrinsic valvular disease or coronary artery disease that needed open-heart surgery.\n3. Patients who had severe heart failure with left ventricle ejection fraction \\\u003C 40%.\n4. Patients whose estimated life expectancy \\\u003C 12 m.\n5. Patient who were non-compliant.\n6. Patients under circumstances which were considered not suitable or prohibitive for participating the clinical trial at the discretion of the attending medical team and the researchers.","8 Years",{"count":59,"type":20},1000,"INTERVENTIONAL",[62],"NA","The primary purpose of this study is to evaluate the feasibility, the safety and the efficacy of the transapical beating-heart septal myectomy for the treatment of hypertrophic obstructive cardiomyopathy. This is a prospective, single-arm, single-center, first-in-man study.",[26],[26,66,67,68,69,70,71,72],"Septal Myectomy","Systolic Anterior Motion","Left Ventricle Outflow Tract Obstruction","Mitral Regurgitation","Transapical","Off-pump","Minimally invasive","2024-11-05",{"date":75,"type":41},"2024-11-07",{"date":77,"type":41},"2022-04-15",{"date":79,"type":20},"2025-12-30",{"name":81,"class":48},"Xiang Wei",1]